G

Genovis AB
STO:GENO

Watchlist Manager
Genovis AB
STO:GENO
Watchlist
Price: 28.05 SEK 3.13% Market Closed
Market Cap: 1.8B SEK
Have any thoughts about
Genovis AB?
Write Note

Genovis AB
Change in Working Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Genovis AB
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
G
Genovis AB
STO:GENO
Change in Working Capital
kr2.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
AddLife AB
STO:ALIF B
Change in Working Capital
-kr274m
CAGR 3-Years
N/A
CAGR 5-Years
-30%
CAGR 10-Years
N/A
BICO Group AB
STO:BICO
Change in Working Capital
kr133.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotage AB
STO:BIOT
Change in Working Capital
-kr119m
CAGR 3-Years
N/A
CAGR 5-Years
-8%
CAGR 10-Years
-20%
MedCap AB (publ)
STO:MCAP
Change in Working Capital
-kr67.6m
CAGR 3-Years
0%
CAGR 5-Years
-17%
CAGR 10-Years
N/A
M
Magle Chemoswed Holding AB
STO:MAGLE
Change in Working Capital
-kr11.9m
CAGR 3-Years
16%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
No Stocks Found

Genovis AB
Glance View

Market Cap
1.8B SEK
Industry
Life Sciences Tools & Services

Genovis AB engages in the research and development of enzyme products. The company is headquartered in Lund, Skane. The company went IPO on 2005-11-11. The firm offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The firm markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.

GENO Intrinsic Value
24.64 SEK
Overvaluation 12%
Intrinsic Value
Price
G

See Also

What is Genovis AB's Change in Working Capital?
Change in Working Capital
2.3m SEK

Based on the financial report for Jun 30, 2024, Genovis AB's Change in Working Capital amounts to 2.3m SEK.

Back to Top